JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

JNJ

227.73

-0.27%↓

ISRG

505.84

-3.26%↓

ABT

105.85

-1.07%↓

MDT

100.64

-0.45%↓

132.22

-1.97%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Avatud

1.23 -2.38

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.27

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+132.56% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-23M 79M
Eelmine avamishind	3.61
Eelmine sulgemishind	1.23

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 23:51 UTC

Tulu

Correction to Samsung Fourth-Quarter Net Profit Article

28. jaan 2026, 23:49 UTC

Kuumad aktsiad

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28. jaan 2026, 23:19 UTC

Tulu

Samsung's Fourth-Quarter Net Profit Beats Consensus

28. jaan 2026, 22:43 UTC

Tulu

Waste Management Logs Higher 4Q Profit as Revenue Rises

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29. jaan 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28. jaan 2026, 23:30 UTC

Market Talk

Tesla to Use Car Factory for Robot Aims -- Market Talk

28. jaan 2026, 23:28 UTC

Tulu

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28. jaan 2026, 23:26 UTC

Tulu

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28. jaan 2026, 23:21 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 23:18 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:58 UTC

Tulu

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28. jaan 2026, 22:48 UTC

Market Talk

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28. jaan 2026, 22:45 UTC

Tulu

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28. jaan 2026, 22:44 UTC

Tulu

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28. jaan 2026, 22:43 UTC

Tulu

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28. jaan 2026, 22:41 UTC

Tulu

Kuumad aktsiad

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28. jaan 2026, 22:41 UTC

Market Talk

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28. jaan 2026, 22:41 UTC

Tulu

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28. jaan 2026, 22:40 UTC

Tulu

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28. jaan 2026, 22:39 UTC

Tulu

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28. jaan 2026, 22:38 UTC

Tulu

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28. jaan 2026, 22:37 UTC

Tulu

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28. jaan 2026, 22:35 UTC

Tulu

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28. jaan 2026, 22:26 UTC

Market Talk

Tulu

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

28. jaan 2026, 22:20 UTC

Market Talk

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

132.56% tõus

12 kuu keskmine prognoos

Keskmine 3 USD 132.56%

Kõrge 4 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.